English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

. Stenting is a widespread procedure for patients suffering from coronary artery disease. The use of drug-covered stents has improved stenting safety and treatment efficiency. Using second-generation Biolimus drug-covered A9 stents is associated with reduced risk of stent thrombosis compared with first-generation ones. The aim of the study was to evaluate two years’ treatment results after implantation of Biolimus A9 stents in coronary arteries in patients who suffer from coronary artery disease. Methods. The study included 216 patients who suffered from coronary artery disease and were treated using Biolimus A9 drug-covered stents, in order to eliminate all greater-than-50% stenoses. Patients’ data were collected from hospital case histories and e-Biomatrix PMR questionnaire. Decisions regarding whether to use Biolimus A9 stents during percutaneous coronary intervention were made by the respective operators. The rate of complication after stenting was evaluated when stenosis was eliminated or reduced to 30% or TIMI 3 flow was determined. Results. Out of 216 patients included in the study, 151 were males (69.91%) and 30.09% (65) were females. Mean of age of patients was 60.2 ± 10.1 years; 19% of patients had diagnosed diabetes. The success rate of implanting Biolimus A9 stents was 100% with no complications during hospital stay.

Evaluation of two years’ treatment results after implantation of Biolimus A9 stents in coronary arteries